What is the recommended treatment regimen for an adult (~70 kg) with concurrent falciparum or vivax malaria and typhoid fever?

Treatment of Concurrent Malaria and Typhoid Fever (Typhomalaria)

Treat both infections simultaneously and independently with appropriate antimalarials based on local resistance patterns plus antibiotics for typhoid fever, as these are distinct infections requiring separate targeted therapy.

Treatment Approach

For Malaria Component

The antimalarial regimen depends critically on the Plasmodium species and local drug resistance patterns:

For P. falciparum (most common in co-infections):

First-line treatment should be artemisinin-based combination therapy (ACT) 1:

• Artemether-lumefantrine: 4 tablets at 0 hours, 4 tablets at 8 hours, then 4 tablets twice daily on days 2-3 (total 24 tablets over 72 hours). Must be taken with fatty food.

• Dihydroartemisinin-piperaquine: 3-4 tablets daily for 3 days (dose based on weight: 3 tablets for 36-75 kg, 4 tablets for >75 kg). Must be taken fasting. Avoid if QTc prolongation risk.

Critical caveat: Chloroquine resistance is now widespread in P. falciparum globally, including Africa 2, 3. The outdated 1992 guidelines [4-4] recommending chloroquine are no longer applicable for most regions. Do not use chloroquine for P. falciparum unless confirmed from Haiti or other rare chloroquine-sensitive areas 3.

Alternative regimens if ACTs unavailable 1:

• Atovaquone-proguanil: 4 tablets daily for 3 days (with fatty food)
• Quinine sulfate 750 mg three times daily for 7 days PLUS doxycycline 100 mg twice daily for 7 days

For P. vivax:

• Chloroquine: 1000 mg initially, then 500 mg at 6,24, and 48 hours 1
• PLUS primaquine 30 mg daily for 14 days for radical cure (check G6PD status first to prevent hemolysis) 1
• If chloroquine-resistant P. vivax suspected, use ACT regimen plus primaquine

For Typhoid Component

Antibiotic selection must be guided by local resistance patterns 5, 6, 7:

• First-line options (if susceptible): Ceftriaxone 2g IV/IM daily for 7-14 days OR ciprofloxacin 500 mg twice daily for 7-10 days
• Avoid empiric use of ampicillin, co-trimoxazole, or chloramphenicol due to widespread resistance 6, 7
• Blood culture and antimicrobial susceptibility testing are essential given high rates of multidrug resistance (up to 29.6% in some regions) 7

Key Clinical Considerations

Diagnostic Pitfalls

• Do not assume all fever in malaria-endemic areas is malaria [4-4]. The presence of Plasmodium on blood smear does not exclude typhoid as cause of fever
• Co-infection rates are relatively low (1.9-5.7%) but clinically significant 6, 7
• Continuous fever pattern and chills are statistically associated with co-infection 7

Treatment Monitoring

• Repeat thick blood smear if symptoms persist beyond 3 days of antimalarial therapy 4
• Monitor for treatment failure suggesting drug resistance
• For severe malaria (any organ dysfunction, high parasitemia, altered consciousness): Use IV artesunate immediately 1, 3

Drug Interactions and Safety

• Avoid combining medications that prolong QTc (artemether-lumefantrine, dihydroartemisinin-piperaquine, and certain fluoroquinolones) 1
• Quinine can cause hypoglycemia; monitor glucose especially in pregnancy 4
• Screen for G6PD deficiency before primaquine use 4, 1

Common Errors to Avoid

1. Using outdated chloroquine-based regimens for P. falciparum - resistance is now global except rare pockets
2. Treating empirically without confirming both diagnoses - leads to inappropriate antibiotic use and resistance 5, 6
3. Assuming Widal test positivity equals active typhoid - blood culture is gold standard 6
4. Forgetting primaquine for P. vivax/ovale - required to prevent relapses from liver hypnozoites 1